Müller L C, Salzer G M, Huber H, Prior C, Ebner I, Frommhold H, Präuer H W
Department of Surgery II, University of Innsbruck, Austria.
Ann Thorac Surg. 1992 Sep;54(3):493-7. doi: 10.1016/0003-4975(92)90441-6.
Since 1977, Innsbruck University Hospital has been employing a multimodal therapy concept for small cell bronchial carcinomas in stages I to IIIa. This concept includes all three treatment forms effective in this tumor, namely, chemotherapy, surgery, and radiotherapy. The therapy scheme is stage-dependent and begins in stages T1-3 N0-1 with lung resection and in stage N2 with chemotherapy. To date, 45 patients have been included in a prospective, nonrandomized (phase II) trial: 7 in TNM stage I, 11 in stage II, and 27 in stage IIIa (6 T3 and 21 N2). The actuarial 5-year survival rate of the entire group (including therapy-related lethality, early recurrences, and protocol violations) is 36%; it is 57% for those in stage I, 28% for those in stage II, and 34% for those in stage IIIa. Median survival time is 18 months. Patients with completed multimodal treatment have a 5-year survival rate of 56% regardless of disease stage. Three patients died of tumor-unrelated causes after 47, 52, and 54 months.
自1977年以来，因斯布鲁克大学医院一直采用多模式治疗方案治疗I至IIIa期小细胞支气管癌。该方案包括对这种肿瘤有效的所有三种治疗方式，即化疗、手术和放疗。治疗方案依分期而定，T1-3 N0-1期始于肺切除术，N2期始于化疗。迄今为止，45例患者被纳入一项前瞻性、非随机（II期）试验：TNM I期7例，II期11例，IIIa期27例（6例T3和21例N2）。整个组（包括与治疗相关的致死率、早期复发和违反方案情况）的精算5年生存率为36%；I期患者为57%，II期患者为28%，IIIa期患者为34%。中位生存时间为18个月。完成多模式治疗的患者，无论疾病分期如何，5年生存率均为56%。3例患者在47、52和54个月后死于与肿瘤无关的原因。
